What's Happening
Johnson & Johnson said its drug Caplyta (lumateperone) met the main goal of a late-stage clinical trial testing it for acute manic episodes associated with bipolar I disorder.
The Phase 3 study found that Caplyta significantly reduced manic symptoms compared with placebo after three weeks of treatment.
The results move Caplyta closer to a potential additional U.S. approval for bipolar mania. The drug is already approved in the United States for bipolar depression and schizophrenia.
What Is Caplyta?
Caplyta is an oral medicine containing lumateperone.
It is a psychiatric medicine that affects several signaling systems in the brain, including serotonin and dopamine pathways.
The drug is already approved for:
- Bipolar depression: Caplyta is approved for depressive episodes associated with bipolar I and bipolar II disorder.
- Schizophrenia: It is also approved for the treatment of schizophrenia in adults.
- Major depressive disorder: Caplyta is approved as an add-on treatment with antidepressants for adults with major depressive disorder.
What it is not yet approved for is acute mania associated with bipolar I disorder.
The new trial is intended to support that additional use.
What Is Bipolar Mania?
Bipolar I disorder involves episodes of depression and mania.
During a manic episode, a person can experience unusually elevated or irritable mood along with increased energy or activity.
Symptoms can include:
- Very high energy
- Racing thoughts
- Reduced need for sleep
- Distractibility
- Inflated sense of importance or ability
- Risk-taking behavior
Mania can become severe enough to require hospitalization.
Treating an acute manic episode quickly is therefore an important part of managing bipolar I disorder.
What the Phase 3 Study Tested
The trial, known as Study 451, was a randomized, double-blind, placebo-controlled Phase 3 study.
It evaluated adults experiencing manic episodes, with or without mixed features, associated with bipolar I disorder.
Participants received either:
- Caplyta 42 mg once daily
- Placebo
Treatment lasted for three weeks.
The primary measure was the change in manic symptoms from the beginning of treatment through Week 3.
The Main Goal Was Met
The study met its primary endpoint.
Patients taking Caplyta experienced a greater reduction in manic symptoms than patients taking placebo.
The difference was measured using the Young Mania Rating Scale, or YMRS, which is commonly used to assess the severity of manic symptoms.
At Week 3, Caplyta produced a 4.8-point greater reduction in YMRS total score compared with placebo.
The result was statistically significant, with a p-value of less than 0.0001.
Improvement Appeared Quickly
One notable finding was the speed of improvement.
J&J said patients showed statistically significant improvement in manic symptoms as early as Day 3.
The benefit continued through the end of the three-week treatment period.
Rapid symptom control can be particularly important in acute mania because severe episodes can escalate quickly and may require hospitalization.
More Patients Achieved a Clinical Response
The study also measured how many patients achieved a clinical response.
A response was defined as at least a 50% reduction in YMRS score.
Approximately:
- 45.8% of patients receiving Caplyta achieved a clinical response.
- Compared with 20.9% receiving placebo.
That means more than twice as many patients in the Caplyta group reached the predefined response threshold.
Overall Illness Severity Also Improved
The trial also met a key secondary endpoint measuring overall illness severity.
Researchers used the Clinical Global Impression-Severity scale, or CGI-S.
At Week 3, patients receiving Caplyta showed significantly greater improvement in overall illness severity compared with those receiving placebo.
So the benefit was not limited to the specific measurement of manic symptoms.
Safety Results Were Consistent With Caplyta's Existing Profile
J&J said the safety and tolerability results were consistent with Caplyta's established safety profile.
The most common treatment-related adverse events occurring at least 5% of the time and at least twice as often as with placebo were:
- Dry mouth: 7.9% with Caplyta versus 3.4% with placebo
- Nausea: 7.9% with Caplyta versus 2.3% with placebo
The company also reported low rates of treatment discontinuation.
However, the study lasted only three weeks, so it provides more limited information about long-term use.
Caplyta Is Already an Established Product
This is not a new medicine entering the market.
Caplyta is already commercially available in the United States and has established approvals in schizophrenia and bipolar depression.
That gives J&J an existing commercial infrastructure, physician familiarity and experience with the drug.
A new approval for bipolar mania could expand the number of situations in which Caplyta can be prescribed.
Why the Mania Indication Could Be Important
Bipolar depression and bipolar mania represent different phases of bipolar I disorder, and treatment approaches can differ.
Caplyta already has an approval covering bipolar depression.
A future approval for acute mania could allow J&J to position the same medicine across both depressive and manic episodes associated with bipolar I disorder, subject to the final FDA-approved labeling.
That could expand Caplyta's role within the bipolar treatment market.
J&J Acquired Caplyta Through a Major Deal
J&J did not originally develop Caplyta.
The company acquired Intra-Cellular Therapies, the drug's original developer, for approximately $14.6 billion in 2025.
The acquisition was aimed at strengthening J&J's neuroscience business, with Caplyta serving as one of the key assets.
The latest clinical results give J&J another opportunity to expand the value of that acquisition by pursuing an additional indication.
This Is the First of Two Pivotal Phase 3 Studies
Study 451 is the first of two pivotal Phase 3 studies evaluating Caplyta for bipolar mania.
J&J said the second study, Study 452, has already been completed and that the company is analyzing the results.
The second trial will therefore be important in determining whether J&J has a broader clinical package to support a regulatory submission.
What Happens Before FDA Approval?
Positive Phase 3 results do not automatically lead to FDA approval.
J&J would need to submit the relevant evidence to the FDA as part of the regulatory process.
The agency would review the clinical results, safety information and proposed indication before making a decision.
The second pivotal study is therefore important because regulators will evaluate the total body of evidence rather than relying only on one trial.
Caplyta Would Enter an Established Bipolar Mania Market
If approved for bipolar mania, Caplyta would enter a market that already includes several established treatments.
These include different types of antipsychotic medicines, mood stabilizers and combination treatments.
J&J would therefore need to establish where Caplyta fits within existing treatment approaches based on its evidence, tolerability, dosing and other clinical factors.
The new indication would expand Caplyta's market, but it would not eliminate competition.
Rapid Improvement Could Be an Important Clinical Feature
The finding that improvement was statistically significant as early as Day 3 could be relevant in the treatment of acute mania.
Physicians often need treatments that can begin controlling severe symptoms quickly.
However, how important the speed of improvement will be in real-world treatment decisions will depend on the full evidence and how Caplyta compares with existing treatment options.
The Treatment Uses a Once-Daily Dose
The Phase 3 study evaluated 42 mg of Caplyta once daily.
Once-daily oral treatment can be convenient compared with medicines requiring multiple daily doses or administration in a healthcare facility.
At the same time, doctors consider many other factors when choosing treatment, including effectiveness, side effects, drug interactions and patient history.
Caplyta's Exact Mechanism Is Not Fully Understood
Lumateperone interacts with several neurotransmitter systems in the brain.
It has activity involving serotonin 5-HT2A receptors and dopamine D2 receptors, among others.
However, the precise mechanism responsible for Caplyta's therapeutic effects is not fully established.
That is not unusual among psychiatric medicines, where clinical effectiveness can be demonstrated even when every part of the underlying biological mechanism is not completely understood.
The Results Strengthen J&J's Neuroscience Portfolio
The bipolar-mania program is part of J&J's broader push in neuroscience.
The company is developing and commercializing medicines across areas including schizophrenia, depression and bipolar disorder.
Expanding Caplyta into another major indication could strengthen its position within that portfolio.
The result is also relevant to J&J's strategy following its acquisition of Intra-Cellular Therapies.
The Results Were Presented at Psych Congress
The Phase 3 findings were presented during the 2026 Psych Congress Annual Meeting.
J&J presented a broad range of neuroscience research during the meeting, including studies of Caplyta, Spravato and other psychiatric treatments.
The bipolar-mania results were among the company's late-breaking clinical presentations.
What the Results Do Not Yet Prove
The findings are important, but there are still limits to what can be concluded from the trial.
The study lasted only three weeks, so it cannot answer every question about long-term treatment.
It also compared Caplyta with placebo rather than directly comparing it with every medicine currently used for acute mania.
And the study involved adults with bipolar I manic episodes, so the results should not automatically be extended to every bipolar disorder population.
Why This Matters
The study gives J&J clinical evidence that Caplyta can reduce acute manic symptoms in adults with bipolar I disorder.
The potential regulatory expansion is particularly important because Caplyta is already approved for schizophrenia and bipolar depression.
A future approval for bipolar mania would allow J&J to expand an established product into another major phase of bipolar I disorder.
The results are also significant from a business perspective because J&J paid approximately $14.6 billion to acquire Intra-Cellular Therapies.
Expanding Caplyta's indications is one way J&J can increase the commercial potential of that investment.
Looking Ahead
J&J is now analyzing results from the second pivotal Phase 3 study of Caplyta in bipolar mania.
The next major step will be determining whether the combined evidence is sufficient to support a regulatory submission.
The FDA would then review the full clinical and safety package before deciding whether to expand Caplyta's label.
If the new indication is approved, J&J will need to establish Caplyta's position within an already competitive bipolar mania treatment market.
What This Means for Healthcare Marketers
This is a strong example of how an established drug can create additional market opportunities through new indications.
The major signals to watch include:
- Clinical-trial results: Positive Phase 3 data can open the door to new indications.
- Regulatory filings: A submission signals movement from clinical development toward a potential label expansion.
- New indications: Additional approved uses can expand the addressable patient population.
- Acquisitions: Large pharmaceutical acquisitions can reveal which therapeutic areas companies expect to drive future growth.
For B2B healthcare companies, tracking clinical-trial milestones, regulatory activity and indication expansions can provide early insight into future pharmaceutical demand.
Key Takeaways
- J&J's Caplyta (lumateperone) met the primary goal of a Phase 3 study in adults with bipolar I mania.
- The trial evaluated 42 mg once daily for three weeks.
- Caplyta produced a 4.8-point greater reduction in YMRS score than placebo at Week 3.
- Significant improvement was observed as early as Day 3.
- About 45.8% of Caplyta-treated patients achieved a clinical response compared with 20.9% on placebo.
- The study also showed significant improvement in overall illness severity.
- The most common treatment-related adverse events were dry mouth and nausea.
- Caplyta is already approved in the U.S. for schizophrenia, bipolar depression and as an adjunctive treatment for major depressive disorder.
- Caplyta is not yet approved for acute bipolar mania.
- J&J acquired Intra-Cellular Therapies for approximately $14.6 billion.
- A second pivotal Phase 3 bipolar-mania study has been completed and is now being analyzed.
- The results could support a future application to expand Caplyta's U.S. approval to include acute manic episodes associated with bipolar I disorder.